216 related articles for article (PubMed ID: 17591829)
1. Erlotinib in cancer treatment.
Bareschino MA; Schettino C; Troiani T; Martinelli E; Morgillo F; Ciardiello F
Ann Oncol; 2007 Jun; 18 Suppl 6():vi35-41. PubMed ID: 17591829
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
3. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Mountzios G; Syrigos KN
Drug Saf; 2011 Mar; 34(3):175-86. PubMed ID: 21332242
[TBL] [Abstract][Full Text] [Related]
4. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Fuster LM; Sandler AB
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
6. Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Fiala O; Pesek M; Finek J; Krejci J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(2):129-34. PubMed ID: 23259780
[TBL] [Abstract][Full Text] [Related]
7. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Harichand-Herdt S; Ramalingam SS
Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. A review of erlotinib and its clinical use.
Tang PA; Tsao MS; Moore MJ
Expert Opin Pharmacother; 2006 Feb; 7(2):177-93. PubMed ID: 16433583
[TBL] [Abstract][Full Text] [Related]
11. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
13. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Pirker R; Minar W; Filipits M
Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
15. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Thomas M
Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
Lu YY; Jing DD; Xu M; Wu K; Wang XP
World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
